Primary hepatocellular carcinoma (HCC, hereinafter referred to as liver cancer) is a malignant tumor originating from liver cells. In China, 85% to 90% of them occur on the basis of post-hepatitis cirrhosis. Liver cancer is a tumor with rich blood supply, and more than 90% of the blood supply comes from the hepatic artery. Embolization of tumor-supplying arteries with embolic agents added with chemotherapeutic drugs is called transcatheter hepatic artery chemoembolization (transcatheter arterial chemoembolization, TACE). This treatment method blocks the blood supply of the tumor on the one hand, and at the same time accumulates high concentration of chemotherapy drugs in the tumor to exert the maximum killing effect on the tumor cells[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]。 The operation methods of TACE are as follows: (1) intraarterial infusion of chemotherapeutic drugs and then arterial embolization (with or without chemotherapeutic drugs in the embolic agent); (2) chemotherapy drug perfusion before and after arterial embolization ("sandwich" therapy); (3) the chemotherapeutic drug and the granular embolic agent are mixed together for embolization; (4) Simply use lipiodol chemotherapy drug emulsion for arterial embolization and/or add granular embolic agent. According to the meta-analysis of domestic and foreign literature, TACE is an interventional therapy that can benefit patients with liver cancer[17,18,19,20]。 It is characterized by wider indications, less trauma, strong repeatability and better curative effect. For patients with intermediate and advanced liver cancer who cannot be surgically resected, TACE should be the first choice for non-surgical treatment.
